Detalhe da pesquisa
1.
Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
J Antimicrob Chemother;
69(3): 728-34, 2014 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24155058
2.
Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.
HIV Clin Trials;
11(4): 175-85, 2010.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20974573
3.
Lack of antiviral activity of darunavir against SARS-CoV-2.
Int J Infect Dis;
97: 7-10, 2020 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32479865
4.
Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
Antivir Ther;
14(5): 713-22, 2009.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19704175
5.
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
Clin Infect Dis;
47(7): 969-78, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18764771
6.
Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Antivir Ther;
13(5): 655-61, 2008.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18771049
7.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet;
370(9581): 29-38, 2007 Jul 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17617270
8.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet;
370(9581): 39-48, 2007 Jul 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17617271
9.
Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers.
J Clin Pharmacol;
48(3): 322-9, 2008 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18195053
10.
A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.
Br J Clin Pharmacol;
66(4): 508-16, 2008 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18492125
11.
Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Pharmacotherapy;
28(10): 1215-22, 2008 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18823217
12.
Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
Ann Pharmacother;
42(6): 757-65, 2008 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18445705
13.
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
AIDS;
21(6): F1-10, 2007 Mar 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17413684
14.
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
Antivir Ther;
12(5): 789-96, 2007.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17713162
15.
Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
AIDS;
20(13): 1721-6, 2006 Aug 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16931936
16.
An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.
AIDS;
17(18): F49-54, 2003 Dec 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14685068
17.
Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
Curr HIV Res;
8(7): 564-76, 2010 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20946097
18.
A review of the safety and tolerability profile of the next-generation NNRTI etravirine.
AIDS Res Hum Retroviruses;
26(7): 725-33, 2010 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20624073
19.
Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance.
Antivir Ther;
15(6): 803-16, 2010.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20834093
20.
Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Clin Ther;
32(2): 328-37, 2010 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20206790